Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response (Q59120277)
Jump to navigation
Jump to search
article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response |
article |
Statements
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response (English)
Karen I Kroeker
Levinus A Dieleman
Brendan P Halloran
Richard N Fedorak
1 September 2015